These findings are consistent with a recent systems serology study reporting that IgA responses targeting the PfCSP NANP repeat region and C-terminus were associated with protection in trials of the malaria vaccine candidate RTS,S/AS01 (40). The gene discussed is NANP; the disease is malaria.